ES2124926T3 - Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas. - Google Patents

Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.

Info

Publication number
ES2124926T3
ES2124926T3 ES95103470T ES95103470T ES2124926T3 ES 2124926 T3 ES2124926 T3 ES 2124926T3 ES 95103470 T ES95103470 T ES 95103470T ES 95103470 T ES95103470 T ES 95103470T ES 2124926 T3 ES2124926 T3 ES 2124926T3
Authority
ES
Spain
Prior art keywords
inflammatory
desoxipergualina
medication
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95103470T
Other languages
English (en)
Inventor
Jurgen Dr Lindner
Gerhard Dr Dickneite
Hans Ulrich Dr Schorlemmer
Klaus Dr Bosslet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Nippon Kayaku Co Ltd
Original Assignee
Microbial Chemistry Research Foundation
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4409804A external-priority patent/DE4409804A1/de
Priority claimed from DE19944415553 external-priority patent/DE4415553A1/de
Application filed by Microbial Chemistry Research Foundation, Nippon Kayaku Co Ltd filed Critical Microbial Chemistry Research Foundation
Application granted granted Critical
Publication of ES2124926T3 publication Critical patent/ES2124926T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE LA UTILIZACION DE DEOXISPERGUALINA PARA ELABORACION DE UN MEDICAMENTO EN LA TERAPIA Y PROFILAXIS DE ENFERMEDADES HIPERREACTIVAS DE INFLAMACION DE SERES HUMANOS Y ANIMALES.
ES95103470T 1994-03-22 1995-03-10 Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas. Expired - Lifetime ES2124926T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4409804A DE4409804A1 (de) 1994-03-22 1994-03-22 Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
DE19944415553 DE4415553A1 (de) 1994-05-03 1994-05-03 Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen

Publications (1)

Publication Number Publication Date
ES2124926T3 true ES2124926T3 (es) 1999-02-16

Family

ID=25934947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95103470T Expired - Lifetime ES2124926T3 (es) 1994-03-22 1995-03-10 Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.

Country Status (11)

Country Link
US (1) US5849799A (es)
EP (1) EP0673646B1 (es)
JP (2) JP3483646B2 (es)
KR (1) KR100338579B1 (es)
AT (1) ATE173921T1 (es)
AU (1) AU712361B2 (es)
CA (1) CA2145211C (es)
DE (1) DE59504374D1 (es)
DK (1) DK0673646T3 (es)
ES (1) ES2124926T3 (es)
NZ (1) NZ270749A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080723B1 (en) * 1998-05-15 2005-03-09 Takara Bio Inc. INHIBITION OF IgA PRODUCTION
DE19923961A1 (de) * 1999-05-25 2000-11-30 Euro Nippon Kayaku Gmbh Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
JP2006117569A (ja) * 2004-10-20 2006-05-11 Juntendo ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851446A (en) * 1984-11-13 1989-07-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Immunosuppressing method
JPS61134312A (ja) * 1984-12-06 1986-06-21 Microbial Chem Res Found 移植免疫抑制剤並びに抗アレルギ−剤
DE3626306A1 (de) * 1986-08-02 1988-02-11 Behringwerke Ag Verwendung von 15-deoxyspergualin als arzneimittel
GB9126870D0 (en) * 1991-12-18 1992-02-19 Fujisawa Pharmaceutical Co Novel compound
US5238689A (en) * 1992-01-07 1993-08-24 Procept, Inc. Use of ruthenium red as immunosuppressive agents
GB9203265D0 (en) * 1992-02-15 1992-04-01 Fisons Plc Pharmaceutically active compound
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa

Also Published As

Publication number Publication date
AU1494395A (en) 1995-09-28
CA2145211C (en) 2002-10-15
US5849799A (en) 1998-12-15
EP0673646A3 (de) 1995-12-27
JP2003286160A (ja) 2003-10-07
AU712361B2 (en) 1999-11-04
DE59504374D1 (de) 1999-01-14
KR100338579B1 (ko) 2002-11-23
ATE173921T1 (de) 1998-12-15
EP0673646A2 (de) 1995-09-27
NZ270749A (en) 1997-03-24
DK0673646T3 (da) 1999-08-16
JP3483646B2 (ja) 2004-01-06
CA2145211A1 (en) 1995-09-23
JPH0840887A (ja) 1996-02-13
KR950031061A (ko) 1995-12-18
EP0673646B1 (de) 1998-12-02

Similar Documents

Publication Publication Date Title
DE3382458D1 (de) Haarwuchsmittel.
DE59108854D1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
DE69418601T2 (de) Guanidinderivate mit therapeutischer wirkung
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
ES2124926T3 (es) Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
ES2094757T3 (es) Un factor megacariocitopoyetico.
MX9301879A (es) Medicamento para el tratamiento de la inflamacion de las vias respiratorias
NO307126B1 (no) Anvendelse av biologisk aktive ureidoderivater for fremstilling av et medikament for bruk i behandlingen av lentivirusindusert sykdom
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
BR9607663A (pt) Uso de penciclovir para o tratamento de herpes-virus 8 humano
ES2109347T3 (es) Utilizacion en terapeutica de picnogenoles para la preparacion de medicamentos con actividad anti-inflamatoria.
MX9102181A (es) Iminobenzodiazepina para el tratamiento de desordenes del sueno
DE69833317D1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
IT1245390B (it) Composizione farmaceutica ad attivita' antivirale

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 673646

Country of ref document: ES